- Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
- Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
- Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
- Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
- Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
- Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
- Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
- Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
- Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
- Intensity Therapeutics Announces Reverse Stock Split
- Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
- Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
